IHC A.I CyberSecurity Scoring
02/04/2026
Access Monitoring Plan
Access Monitoring Plan
No incidents recorded for inVentiv Health Commercial in 2026.
No incidents recorded for inVentiv Health Commercial in 2026.
No incidents recorded for inVentiv Health Commercial in 2026.
Pharmaceutical Manufacturing
At MSD, known as Merck & Co., Inc., Rahway, NJ, USA in the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. We aspire to be the premier research-intensive biopharmaceutical company in the world – and today, we are at the forefront of research to deliver innovative health solutions that advance the prevention and treatment of diseases in people and animals. We foster a diverse and inclusive global workforce and operate responsibly every day to enable a safe, sustainable and healthy future for all people and communities. For more information, visit www.msd.com and connect with us on Facebook, Instagram, Twitter, and YouTube.
Torrent Pharma, with annual revenues of more than Rs 10,700 crores, is the flagship Company of the Torrent Group, with group revenues of Rs 41,000 crores. It is ranked 5th in the Indian Pharma Market and is among the Top 5 in the therapeutic segments of Cardiovascular (CV), Central Nervous System (CNS), Gastro-intestinal (GI), Vitamins Minerals Nutritionals (VMN) and Cosmo-Dermatology. The Company also has significant presence in diabetology, pain management, gynaecology, oncology and anti-infective segments. Torrent has 8 manufacturing facilities , of which 5 are USFDA approved. With R&D as the backbone for its growth in domestic & overseas market, it has invested significantly in R&D capabilities with state-of-the-art R&D infrastructure employing around 800 scientists. The acquisition of Elder Pharma's Indian branded business in 2013, Dermaceuticals business of Zyg Pharma in 2015, API plant of Glochem Industries in 2016, Women healthcare brands from Novartis and Unichem's Indian branded business along with its Sikkim Plant in 2017 strengthened Torrent Pharma's position in the Indian Pharma market. Torrent Pharma started international acquisitions in 2005 with entry into the German market. Today, the Company has presence in more than 50 countries and is ranked No. 1 among the Indian pharma Companies in Brazil and Germany. Torrent Pharma is committed towards “not just healthcare but lifecare.”
Championing the missions that matter™. Catalent, Inc. is a leading global contract development and manufacturing organization (CDMO) and trusted partner to pharma, biotech, and consumer health companies worldwide. We put patients first in everything we do, helping people live better and healthier lives through every product we help develop, manufacture and deliver. With over 1,000 active development programs at any given time, we launch over 100 new products and line extensions annually. Catalent has supported half of all FDA approvals over the past decade, and our teams working at over 40 global sites help us produce over 60 billion doses every year. Our strength lies in our people: teams across our more than 40 sites and thousands of passionate scientists and technicians who bring expertise in development sciences, delivery technologies, and multi-modality manufacturing. What unites us is our commitment to championing our partners’ missions as our own, anticipating customer needs, solving complex challenges and ultimately making a difference in the lives of patients across the globe. At Catalent, you will be able to directly have an impact, solving problems and ensuring excellence for our customers. Our focus on delivering meaningful outcomes alongside our customers means your work directly impacts millions of people around the world. Join us in championing the missions that matter. Catalent is headquartered in Tampa, Florida, with over 40 global sites. Visit www.catalent.com to learn more.
For almost 50 years, we’ve been creating high-quality medicines and making them accessible to the people who need them. We are a trusted, reliable partner and dependable source of over 800* high-quality generic, specialty and branded pharmaceutical products that hospitals, physicians and pharmacists need to treat their patients across North America, MENA and Europe. We have 29 manufacturing plants, 3 R&D hubs and c9,500 employees worldwide. *As of December 2025 Subscribe to our channel on YouTube https://youtube.com/@hikmapharmaceuticals5668 For all product information and enquiries, please contact us at [email protected]
Glenmark Pharmaceuticals Limited is a research-led, global organization committed to enriching lives. Innovation is deeply embedded in Glenmark’s culture; it is how we differentiate ourselves in our key markets and create greater value for our stakeholders. In our journey of innovation over the past four and a half decades, we have evolved from a generics company to a global organization offering specialty and branded products. Glenmark’s core values of Achievement, Respect, and Knowledge impart a sense of organizational unity that drives our growth. We have established a robust global branded generics, specialty, and OTC business; with a significant presence in the therapy areas of dermatology, respiratory, and oncology. Our ten state-of-the-art manufacturing facilities spread across four continents with operations in over 80 countries help us impact millions of patients across the globe. We recently consolidated our innovation efforts in small molecules and biologics research with the formation of ‘Ichnos Glenmark Innovation’ (IGI). This alliance is aimed at leveraging the capabilities of Glenmark and its subsidiary, Ichnos Sciences, to accelerate innovation in cancer treatment. To know more about IGI, check out: https://iginnovate.com/ Sustainability is an integral aspect of all our operations and we are focused on achieving our Environment, Social and Governance (ESG) goals. Our responsibility also extends to our communities, and over the years, our CSR efforts have touched the lives of over 3 million people.
As a global healthcare company, Fresenius Kabi is Committed to Life. The company’s products, technologies, and services are used for the therapy and care of critically and chronically ill patients. With over 41,000 employees and present in over 100 countries, Fresenius Kabi’s expansive product portfolio focuses on providing access to high-quality and lifesaving medicines and technologies. In Biopharma, Fresenius Kabi offers cutting-edge biosimilars for autoimmune diseases and oncology. With leading market positions in Clinical Nutrition, a broad portfolio of enteral and parenteral products makes a distinct difference in patients’ nutritional status. In MedTech, the company provides vital infusion pumps, cell and gene therapy devices, disposables, and more. Fresenius Kabi is the global leader in supplying blood collection bags and devices, supporting blood banks and healthcare facilities worldwide. The company’s I.V. Generics and Fluids for infusion therapy help save millions of lives every year, in emergency medicine, surgery, oncology, and intensive care. Fresenius Kabi takes a holistic approach to healthcare and uniquely combines experience, expertise, innovation, and dedication – making a difference in the lives of 450 million patients annually. With the #FutureFresenius strategy, the company is developing, producing, and selling new products and technologies and aspires to expand its position as a leading global provider of therapies, improve patient care, generate sustainable value for stakeholders – shaping the future of healthcare. Fresenius Kabi is an operating company of the Fresenius Group, founded in 1912, along with Helios and Quirónsalud. As ONE team, the companies in the Fresenius Group are committed to providing lifesaving and life-changing healthcare solutions on a global scale. User information & community guidelines: https://www.fresenius-kabi.com/social-media-terms-conditions Imprint: www.fresenius-kabi.com/imprint
This channel is not intended for U.S. and Canadian visitors. Merck operates in the U.S. and Canada as EMD Serono in Healthcare, MilliporeSigma in Life Science and EMD Electronics in Electronics. An unaffiliated and unrelated company, Merck & Co., Inc., Kenilworth, NJ, US holds the rights in the trademark MERCK in the U.S. and Canada. _______________________________ We are Merck, a leading global science and technology company headquartered in Germany. We are curious explorers, courageous pioneers, and ingenious inventors. Our colleagues across the globe love innovating with science and technology to enrich people’s lives with our solutions in Life Science, Healthcare, and Electronics. Together, we dream big and are passionate about caring for our rich mix of people, customers, patients, and the planet. We believe in the positive power of science and technology. It has determined our actions since 1668 and inspires us to continue researching for a future worth living. As a family-owned company with over 350 years of experience, we stand for sustainability, responsibility, and innovative strength. We take pride in being a diverse and inclusive company that values and fosters the talents and abilities of our employees. That's why we are always looking for curious minds that see themselves imagining the unimaginable with us. Work your Magic and join Merck. Legal Disclaimer: www.merckgroup.com/en/legal-disclaimer.html Data Privacy Declaration: www.merckgroup.com/en/privacy-statement
At Merck, known as MSD outside of the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. We aspire to be the premier research-intensive biopharmaceutical company in the world – and today, we are at the forefront of research to deliver innovative health solutions that advance the prevention and treatment of diseases in people and animals. We foster a diverse and inclusive global workforce and operate responsibly every day to enable a safe, sustainable and healthy future for all people and communities. For more information, visit www.merck.com. This site is intended for residents of the United States and Canada and their territories only. FLS: http://merck.us/3TKXNuZ
At Johnson & Johnson Innovative Medicine, we innovate with purpose, to lead where medicine is going. The experiences of patients around the world inform and inspire our science-based innovations, which continue to change and save lives. Applying rigorous science with compassion, we confidently address the most complex diseases of our time and develop the potential medicines of tomorrow. We are continuously working to develop treatments, aspiring to find cures, pioneering the path from lab to life, and championing patients every step of the way. https://bit.ly/3reuMvK
Latest updates, reports, and threat intel affecting the global network.
From AI-driven automation to sustainable tech solutions, several emerging Australian startups are redefining industries and setting new benchmarks in...
Brisbane's Tech Surge: With $10.8B in value and 81% growth, Brisbane offers strong government backing, top talent, and global reach.
Discover how AI in transportation software development drives efficiency, safety, and sustainability through predictive analytics and...
This blog will help you understand everything related to AI in eCommerce and how it's transforming the landscape of online retail.
Key takeaways: For most Australian businesses today, cybersecurity has become as crucial as finance or operations; there is no separating it...
We will explore the myriad types of cyber threats that healthcare institutions face, highlight best practices for mitigating these risks, examine real-world...
Making use of one of its divisions, Addison Whitney, whose business includes generating the brand names of many recently commercialized...
FOSSBilling is a free, open-source billing and client management system. In versions 0.5.6 through 0.7.2, when a `ClientPasswordReset` record already exists for a client (from a previous unexpired reset request), subsequent calls to the `reset_password` guest API endpoint reuse the existing token instead of generating a new one. The 15-minute validity window is anchored to the first request's `created_at` timestamp, not the time of the most recent email. An attacker who obtained the original reset link remains able to use it even after the victim requests a new reset, because the original token is never invalidated or rotated. Version 0.8.0 patches the issue. Some workarounds are available. Configure a reverse proxy (e.g., Nginx, Apache, Cloudflare) to apply per-IP rate limiting to the `/client/reset-password` endpoint to minimize the window of opportunity, and/or manually clear expired `client_password_reset` records from the database after a client reports a suspected compromise.
FOSSBilling is a free, open-source billing and client management system. Versions prior to 0.8.0 allow a low-privileged staff account to grant arbitrary module permissions to itself through the admin API, resulting in persistent privilege escalation. A staff user that only has `staff.create_and_edit_staff` can call `/api/admin/staff/permissions_update` targeting their own account and write any permission structure, bypassing the intended role-based access control boundary. Version 0.8.0 patches the issue. Some workarounds are available. Restrict the `staff.create_and_edit_staff` permission to only highly trusted staff members and/or use a reverse proxy or WAF to restrict access to `/api/admin/staff/permissions_update` to specific trusted roles.
FOSSBilling is a free, open-source billing and client management system. Versions 0.5.3 through 0.7.2 allow authenticated clients to both read and reset API key service secrets for orders that are no longer in an `active` state (e.g., `suspended`, `canceled`). The root cause is missing order-state validation in two client API endpoints, despite an `isActive()` helper already existing in the `Serviceapikey` module and the frontend UI correctly gating access on `order.status == 'active'`. Version 0.8.0 contains a fix. Some workarounds are available. If the `Serviceapikey` module is not needed, uninstall it to remove the affected endpoints. One may also use a reverse proxy or WAF to restrict access to `/api/client/order/service` and `/api/client/serviceapikey/reset` based on application-level order-state logic.
FOSSBilling is a free, open-source billing and client management system. Versions prior to 0.8.0 allow low-privileged staff accounts to perform unauthorized actions via admin API endpoints. The root cause is a combination of the `can_always_access` module flag (which grants all staff access to certain modules) and insufficient permission checks or unsafe parameter handling on individual endpoints. Version 0.8.0 contains a fix. Some workarounds are available. Restrict staff accounts to only those who need access to sensitive settings and/or use a reverse proxy or WAF to restrict access to the affected endpoints to trusted IP addresses or higher-privilege roles.
FOSSBilling is a free, open-source billing and client management system. In versions 0.5.6 through 0.7.2, when the "Require Email Confirmation" setting is enabled, a logged-in client with an unverified email address (`email_approved = 0`) can access all client-area pages (e.g. `/client/balance`, `/client/order/list`, `/client/invoice`) and read real account data, including wallet balances and transaction history. The API-side enforcement correctly restricts unverified clients to only profile-related endpoints, but the page-side enforcement is overly permissive, allowing any request whose path starts with `/client`. Version 0.8.0 contains a fix. No known workarounds that don't involve modifying the source code are available.
curl -i -X GET 'https://api.rankiteo.com/underwriter-getcompany-history?
linkedin_id=axa' -H 'apikey: YOUR_API_KEY_HERE'
Every week, Rankiteo analyzes billions of signals to give organizations a sharper, faster view of emerging risks. With deeper, more actionable intelligence at their fingertips, security teams can outpace threat actors, respond instantly to Zero-Day attacks, and dramatically shrink their risk exposure window.
Rankiteo is a unified scoring and risk platform that analyzes billions of signals weekly to help organizations gain faster, more actionable insights into emerging threats. Empowering teams to outpace adversaries and reduce exposure.